Covered recipient · General Payments record
KIMBERLY S LASSWELL
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$2,759.43
- Reported across 195 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $579.34 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $187.75 | 13 |
| PFIZER INC. | $86.95 | 5 |
| Bausch Health US, LLC | $83.86 | 4 |
| ALK-Abello, Inc | $45.46 | 2 |
| Novo Nordisk AS | $40.01 | 2 |
| Amgen Inc. | $32.14 | 2 |
| SHIELD THERAPEUTICS INC | $29.00 | 2 |
| Abbott Laboratories | $22.11 | 1 |
| IBSA Pharma Inc. | $21.50 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.28 | 1 |
| Acerta Pharma LLC | $14.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.11 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124971721 | CMS |
| ALK-Abello, Inc | $21.21 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099892453 | CMS |
| ALK-Abello, Inc | $24.25 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099892455 | CMS |
| Amgen Inc. | $17.44 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117607048 | CMS |
| Amgen Inc. | $14.70 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117607050 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.28 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105674251 | CMS |
| Bausch Health US, LLC | $21.28 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148031162 | CMS |
| Bausch Health US, LLC | $22.31 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148031164 | CMS |
| Bausch Health US, LLC | $17.90 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148031166 | CMS |
| Bausch Health US, LLC | $22.37 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148031168 | CMS |
| IBSA Pharma Inc. | $21.50 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142985978 | CMS |
| Lilly USA, LLC | $18.23 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135773090 | CMS |
| Lilly USA, LLC | $0.72 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135799746 | CMS |
| Lilly USA, LLC | $28.12 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135773092 | CMS |
| Lilly USA, LLC | $1.84 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135779358 | CMS |
| Lilly USA, LLC | $0.37 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135782016 | CMS |
| Lilly USA, LLC | $20.44 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135779356 | CMS |
| Lilly USA, LLC | $18.15 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135761362 | CMS |
| Lilly USA, LLC | $1.27 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135779360 | CMS |
| Lilly USA, LLC | $12.72 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135737286 | CMS |
| Lilly USA, LLC | $20.07 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135761364 | CMS |
| Lilly USA, LLC | $21.25 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135799744 | CMS |
| Lilly USA, LLC | $22.94 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135761366 | CMS |
| Lilly USA, LLC | $21.63 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135761368 | CMS |
| Novartis Pharmaceuticals Corporation | $16.28 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087129368 | CMS |
| Novo Nordisk Inc | $19.54 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100444811 | CMS |
| Novo Nordisk Inc | $20.47 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100379667 | CMS |
| PFIZER INC. | $16.08 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131023993 | CMS |
| PFIZER INC. | $16.39 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131382206 | CMS |
| PFIZER INC. | $14.88 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131931882 | CMS |
| PFIZER INC. | $16.36 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132123026 | CMS |
| PFIZER INC. | $23.24 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131228618 | CMS |
| SHIELD THERAPEUTICS INC | $14.56 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150121649 | CMS |
| SHIELD THERAPEUTICS INC | $14.44 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150125031 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.